Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy

INCLUSION CRITERIA: * Patient and family must agree to return to the clinic up to 8 times within 2 months * Children ≥ 8 and \<18 years of age at the time of study entry who were previously treated for: * a hypothalamic tumor * mid-line brain tumor * a tumor involving one or both thalami * craniopharyngioma * diagnosis of hydrocephalus secondary to a brain tumor or treatment of a brain tumor that required placement of a permanent shunt. * Off cancer treatment for at least six months * Proficient in English * Able to swallow capsules * Experiencing symptoms of excessive daytime sleepiness (EDS) for at least three months prior to study entry that is not a result of inadequate sleep hygiene or other known medical disorder. * Negative pregnancy test EXCLUSION CRITERIA: * Patients treated with doxorubicin or high dose cyclophosphamide * History of a clinically significant drug sensitivity to methylphenidate, modafinil, armodafinil or any of their components * Known cardiac disorders including arrhythmias, hypertension requiring treatment or structural heart disease * Have taken methylphenidate or modafinil within the last 14 days * Current/concurrent use of antihistamines, benzodiazepine, anticonvulsants or alcohol * Clinical diagnosis of major depression, subclinical depression, or anxiety disorder * History of psychosis or mania * Patients with suicidal ideation * Diagnosis with anemia, untreated hypothyroidism, mononucleosis or narcolepsy * History of substance abuse * Pregn…